top of page

Another successful exit for Redalpine




The new year starts off with exciting news for our Redalpine Capital I (RAC I) investors: with Biognosys, the leading solution provider for next generation proteomics, we have achieved yet another exit for our first fund. In the course of a substantial equity financing round, Redalpine has divested its stake in Biognosys to a corporate investment fund. With RAC I in its harvesting phase, this transaction represented an opportunity to secure an attractive multiple on our investment. This exit is yet another affirmation of Redalpine’s leading role as early stage investor.


Redalpine was Biognosys’ first investor and has accompanied the company since 2009 to see it grow from an ETH spin-off into the global technology leader in the field of proteomics. Today, Biognosys’ technology enables accelerated discovery of drug targets, biomarkers, and personalized medicine for their customers, including many of the top pharma companies.


The current financing round will allow further strengthening of Biognosys’ commercial operations and expansion of its global footprint, starting with the establishment of its US subsidiary.

Commentaires


bottom of page